On Feb. 17, 2022, Novavax announced that Health Canada had granted authorization for Nuvaxovidﾙ COVID-19 Vaccine (Recombinant protein, Adjuvanted) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.

The vaccine, also known as NVX-CoV2373, was the first protein-based vaccine to be authorized for use in Canada.